Novo's Q2 Beat Masks a 7% Growth Trap: Is the Wegovy Pill Saving the Story?

A beat improved sentiment, but it did not settle the pricing debate

Novo gave the market the kind of quarter that reduces panic. It posted second-quarter adjusted operating profit above forecasts and raised its full-year profit and sales outlook. That matters. But relief can make investors mistake "better than feared" for "problem solved."

Revenue growth looked steadier, but the quality of that growth still matters

Adjusted sales grew 7% in Q2 2026, helped by strong GLP-1 volume growth in obesity care and the strong performance from its newly launched Wegovy pill. For a business that has lived through a share price slide that has erased more than $400 billion in market value since its 2024 peak, that is enough to calm nerves. It does not, on its own, prove that the pricing reset is over.

The useful reading of the quarter is straightforward: demand is still there, and the oral launch is helping. What remains unfinished is whether Novo can turn that demand into cleaner revenue and sustain higher guidance for more than one reporting cycle.

Volumes helped Q2, but lower realized prices still capped the headline

Novo generated DKK 78.5 billion in Q2 sales, up 7% at CER, while adjusted operating profit was DKK 33.4 billion, up 11% at CER. That gap matters. It suggests volumes did most of the heavy lifting, while lower realized prices kept the revenue line from looking as strong as the profit line.

Novo's own summary put the two dynamics side by side: strong GLP-1 volume growth in obesity care arrived alongside lower realized prices and US pricing pressure. In other words, the business is still growing through the product portfolio, but the market remains focused on how much of that growth survives after price concessions.

What the Wegovy pill actually proved

The clearest bullish point is adoption. The WegovyⓇ pill captured 90% of the US oral obesity market and achieved over 5 million cumulative prescriptions in 30 weeks. That is meaningful evidence that Novo still has commercial momentum and at least one credible new growth lever inside obesity care.

But a successful launch does not automatically end a price war. The pill helps only if the extra volume is enough to outweigh the margin and pricing pressure still affecting the category.

Why investors may be rerating the stock too early

After a long drawdown, investors are often eager to believe the turnaround story. Novo's second-quarter adjusted operating profit above forecasts and raised its full-year profit and sales outlook made that impulse understandable. Still, the cleaner debate is:

• Bull case: strong obesity volumes and fast oral uptake can rebuild growth before pricing fully normalizes.
• Bear case: the market is rewarding volume strength too early while underestimating how long US pricing pressure will weigh on revenue quality.

The next few weeks matter more than the Q2 headline

Q2 eased the worst of the panic. The next few weeks should show whether that relief deserves to turn into a fuller rerating.

The calendar gives investors two clear checkpoints

Novo reported its Q2 beat earlier this month, and the next hard checkpoint arrives on 4 November 2026, when it will report results for the first three quarters of 2026. That follows the Capital Markets Day 21 September 2026, when management said it would review strategy, operations, and financial targets. This is the window where investors will learn whether management is merely extending relief or rebuilding confidence in a more durable way.

Cash generation matters, but it is not the same as pricing recovery

Novo also produced free cash flow of DKK 42.5 billion in Q2 and declared an interim dividend of DKK 3.75 per share. That matters. Strong cash generation gives the business room to navigate a messy transition.

Still, cash is not the same thing as cleaner pricing. The more important question is whether Novo can pair that financial strength with evidence that margin pressure is stabilizing and that the raised 2026 outlook reflects a more durable improvement rather than a one-quarter rebound.

What would support a higher valuation, and what would break it

Rerate triggers - Management uses the September Capital Markets Day to show a credible path back to higher-quality growth, not just better sentiment. - The November update shows that pricing pressure is not worsening faster than volume can absorb it. - Wegovy pill uptake continues to broaden beyond the initial launch burst.

Invalidation cues - Pricing pressure worsens faster than volumes can offset it. - Margins stall while management leans harder on guidance after previously facing weaker than expected sales and other setbacks. - Dividends and cash flow start to look more like a cushion than a sign of underlying strength.